• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Halozyme Therapeutic (NQ: HALO )

    53.99 -0.31 (-0.57%)
    Streaming Delayed Price Updated: 3:55 PM EDT, Jul 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 384,844
    Open 54.55
    Bid (Size) 53.97 (1)
    Ask (Size) 53.99 (1)
    Prev. Close 54.30
    Today's Range 53.66 - 54.59
    52wk Range 32.83 - 55.82
    Shares Outstanding 142,334,900
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition
    These biotech stocks have promising outlooks that will bring major fortune to investors. Buy before it is too late. 
    Via InvestorPlace
    NASDAQ:HALO is showing good growth, while it is not too expensive.
    HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is not too expensive for the growth it is showing. 
    Via Chartmill

    Performance

    YTD
    +44.40%
    +44.40%
    1 Month
    +7.40%
    +7.40%
    3 Month
    +42.79%
    +42.79%
    6 Month
    +54.57%
    +54.57%
    1 Year
    +28.58%
    +28.58%

    More News

    Read More
    Biotech Arvinas Stock Earns 82 RS Rating
    Via Investor's Business Daily
    Denali Therapeutics Stock Gets Technical Rating Upgrade
    Via Investor's Business Daily
    What 13 Analyst Ratings Have To Say About Halozyme Therapeutics
    Via Benzinga
    3 Biotech Stocks to Buy Now: Q3 Edition
    Via InvestorPlace
    NASDAQ:HALO qualifies as a high growth stock and is consolidating.
    Via Chartmill
    NASDAQ:HALO Shows Potential for a Breakout.
    Via Chartmill
    Decoding 12 Analyst Evaluations For Halozyme Therapeutics
    Via Benzinga
    NASDAQ:HALO appears to be flying under the radar despite its strong fundamentals.
    Via Chartmill
    3 Highly Rated Biotech Stocks for Your July Buy List
    Via InvestorPlace
    3 Breakout Biotech Stocks on Track to Double by 2032
    Via InvestorPlace
    UroGen Pharma Stock Earns 91 RS Rating
    Via Investor's Business Daily
    Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation.
    Via Chartmill
    Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval
    Via Investor's Business Daily
    NASDAQ:HALO: a strong growth stock preparing for the next leg up?.
    Via Chartmill
    Arcellx Stock Earns Relative Strength Rating Upgrade
    Via Investor's Business Daily
    Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
    Via Investor's Business Daily
    Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag.
    Via Chartmill
    The 3 Best Healthcare Stocks to Buy in June 2024
    Via InvestorPlace
    Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
    Via Investor's Business Daily
    Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
    Via Investor's Business Daily
    Krystal Biotech Stock Sees RS Rating Jump To 91
    Via Investor's Business Daily
    Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
    Via Benzinga
    Halozyme Therapeutics Scores RS Rating Jump To 91
    Via Investor's Business Daily
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.